We don’t have a webinar scheduled at the moment, but more exciting sessions are on the way! Check back soon for details, or sign up for our newsletter to be notified when new webinars are announced.
Sign up for our newsletter!
Past AMDA Webinars
Biomarkers of Central Nervous System Involvement in Pome Disease
Title: BiomarkersA measurable sign in the body that helps track disease progression or treatment response. of Central Nervous System Involvement in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart.: New Learnings
Date: Thursday, September 24, 2026
Time: 10 a.m. CT / 11 a.m. ET
Speaker:
Kristen Hagarty-Waite, PhD, RDN, LDN
Summary:
Central nervous system (CNS) manifestations persist in patients with Pompe disease, despite enzymeA protein that helps the body carry out chemical reactions. replacement therapy, as current formulations cannot cross the blood brain barrier. Plasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) have emerged as biomarkers to monitor CNS involvement in Pompe disease, particularly for those with the infantile-onset phenotype. In this presentation, we will share our learnings, so far, regarding biomarkers of CNS involvement.
What Do Your Pompe Test Results Really Mean?
Title: What Do Your Pompe Test Results Really Mean? The Evolution of Pompe Diagnostics: Past, Present, and Future
Date: Thursday, August 20, 2026
Time: 1 p.m. CT / 2 p.m. ET
Speaker:
Deeksha Bali, PhD, FACMG
Summary:
This webinar examines Pompe disease diagnosis in the newborn screening era, drawing on lessons learned since implementation and the growing challenge of novel variants identified each year. It highlights the role of CRIM testing, GAA enzyme and mutationA change in a gene that can affect how it works. analysis, and urine Hex4 biomarker testing in achieving early, accurate diagnosis. The talk underscores an urgent need for a validated, disease-specific functional assay to characterize variants of unknown significance and support their reclassification, benefiting newly diagnosed patients. It also points to the promise of understanding Pompe disease’s molecular mechanisms to predict disease onset and progression and guide treatment decisions, an unmet need for patients identified through newborn screening.
Mental Health for Pompe Disease: The Importance of Being Understood
Title: Mental Health for Pompe Disease: The Importance of Being Understood
Date: Thursday, May 14, 2026
Speakers:
Heather Shorten
Nadia Bodkin, Pharm. D., MS
JC Muyl
Summary:
Living with Pompe disease means navigating far more than the physical realities of a complex, progressive condition. The emotional and psychological toll, including the uncertainty, the isolation, and the challenge of finding care that truly sees the whole person, is a dimension of this journey that is too often left unaddressed. This webinar brings together three advocates at the forefront of mental health and rare disease: Heather Shorten of Pompe Alliance, Nadia Bodkin of the Rare Advocacy Movement, and JC Muyl of Mental Health For Rare.
Drawing on community research and lived experience, our presenters will explore the unique emotional challenges tied to living with Pompe disease, why feeling understood matters so deeply, and what meaningful mental health support can look like for this community. Whether you are a patient, caregiver, healthcare provider, or advocate, this is an opportunity to be part of an important and long-overdue conversation about whole-person care in the Pompe disease community.